Tag Archives: Eneboparatide

EQT Life Sciences Portfolio Company Amolyt Pharma Acquired by Alexion, AstraZeneca Rare Diseases for $1.05 Billion

(IN BRIEF) EQT Life Sciences announces the acquisition of its portfolio company, Amolyt Pharma, by Alexion, AstraZeneca Rare Diseases, for a total deal value of $1.05 billion. This acquisition underscores Amolyt’s significant advancements in developing novel treatments for rare endocrine … Read the full press release